KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Receivables - Other (2018 - 2025)

Travere Therapeutics' Receivables - Other history spans 9 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Receivables - Other fell 43.48% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 43.48%, while the annual FY2025 figure was $1.3 million, 43.48% down from the prior year.
  • Receivables - Other reached $1.3 million in Q4 2025 per TVTX's latest filing, down from $1.5 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $4.6 million in Q4 2023 to a low of $900000.0 in Q4 2021.
  • Average Receivables - Other over 5 years is $2.4 million, with a median of $2.2 million recorded in 2024.
  • Peak YoY movement for Receivables - Other: skyrocketed 142.11% in 2023, then tumbled 50.0% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $900000.0 in 2021, then soared by 111.11% to $1.9 million in 2022, then surged by 142.11% to $4.6 million in 2023, then crashed by 50.0% to $2.3 million in 2024, then crashed by 43.48% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Receivables - Other are $1.3 million (Q4 2025), $1.5 million (Q3 2025), and $1.5 million (Q2 2025).